WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (NASDAQ:NURO) today reported the commercial launch of DPNCheck in Mexico. The initial DPNCheck order will be utilized by one of Mexico’s six major government healthcare institutions to improve the detection of diabetic neuropathy and advance the overall management of diabetes in their patient population.
